Millennium Management’s Adaptive Biotechnologies ADPT Stock Holding History

Millennium Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100,000	Closed	-$671K	–	6060
2023 Q2	$671K	Sell	100,000 -70,000	-41%	-$520K	﹤0.01%	4337
2023 Q1	$1.5M	Buy	+170,000	New	+$1.5M	﹤0.01%	3712
2021 Q4	–	Sell	-10,000	Closed	-$340K	–	6706
2021 Q3	$340K	Buy	+10,000	New	+$362K	﹤0.01%	5722
2021 Q2	–	Sell	-10,000	Closed	-$403K	–	6455
2021 Q1	$403K	Buy	10,000 +5,000	+100%	+$271K	﹤0.01%	5002
2020 Q4	$296K	Buy	+5,000	New	+$258K	﹤0.01%	4555
2020 Q1	–	Sell	-20,000	Closed	-$598K	–	3782
2019 Q4	$598K	Buy	+20,000	New	+$574K	﹤0.01%	3275

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's ADPT Position: Q1 2026 in Review

Millennium Management increased its Adaptive Biotechnologies (ADPT) stake by 5,791% in Q1 2026, buying an estimated $16.9M and bringing the position to 1,081,366 shares worth $15M. The position accounts for 0.01% of the portfolio, ranked #1790.

Millennium Management first reported a position in ADPT in Q2 2019 and has held it in 22 quarters since. The position peaked at $48.1M in Q3 2024. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

Millennium Management held 1,081,366 shares of Adaptive Biotechnologies worth $15M as of Q1 2026.
Millennium Management bought 1,063,009 Adaptive Biotechnologies shares in Q1 2026, an estimated $16.9M.
Adaptive Biotechnologies made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1790 holding.
Millennium Management first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 22 quarters since.
Millennium Management's Adaptive Biotechnologies position peaked at $48.1M in Q3 2024.
295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.